134 related articles for article (PubMed ID: 35984904)
21. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
22. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
[TBL] [Abstract][Full Text] [Related]
23. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
24. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
Kröger N; Bacher U; Bader P; Böttcher S; Borowitz MJ; Dreger P; Khouri I; Olavarria E; Radich J; Stock W; Vose JM; Weisdorf D; Willasch A; Giralt S; Bishop MR; Wayne AS
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1325-46. PubMed ID: 20637879
[TBL] [Abstract][Full Text] [Related]
25. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
26. Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation.
Wong E; Davis JE; Grigg A; Szer J; Ritchie D
Bone Marrow Transplant; 2019 Feb; 54(2):175-189. PubMed ID: 29904127
[TBL] [Abstract][Full Text] [Related]
27. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
28. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yan N; Wang N; Wang G; Huang L; Li C; Wang D; Wang J; Huang L; Meng F; Wei J; Chen L; Mao X; Zhou J; Zhang Y; Cao Y
Cytotherapy; 2022 Aug; 24(8):841-849. PubMed ID: 35256277
[TBL] [Abstract][Full Text] [Related]
29. Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies.
Schuler E; Boughoufala S; Rautenberg C; Nachtkamp K; Dienst A; Fenk R; Haas R; Kondakci M; Germing U; Schroeder T; Kobbe G
Ann Hematol; 2019 May; 98(5):1225-1235. PubMed ID: 30923997
[TBL] [Abstract][Full Text] [Related]
30. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.
Fefer A; Robinson N; Benyunes MC; Bensinger WI; Press O; Thompson JA; Lindgren C
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S48-53. PubMed ID: 9457394
[TBL] [Abstract][Full Text] [Related]
33. Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation.
Minculescu L; Fischer-Nielsen A; Haastrup E; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Sengelov H; Marquart HV
Front Immunol; 2020; 11():1068. PubMed ID: 32547559
[TBL] [Abstract][Full Text] [Related]
34. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Waller EK; Boyer M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
[TBL] [Abstract][Full Text] [Related]
35. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
Zaghi E; Calvi M; Di Vito C; Mavilio D
Front Immunol; 2019; 10():2794. PubMed ID: 31849972
[TBL] [Abstract][Full Text] [Related]
36. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
37. Deregulated Expression of Circular RNAs Is Associated with Immune Evasion and Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Zhao F; Zhang X; Pei X; Yang D; Han M
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360223
[TBL] [Abstract][Full Text] [Related]
38. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Davids MS; Kim HT; Costello C; Herrera AF; Locke FL; Maegawa RO; Savell A; Mazzeo M; Anderson A; Boardman AP; Weber A; Avigan D; Chen YB; Nikiforow S; Ho VT; Cutler C; Alyea EP; Bachireddy P; Wu CJ; Ritz J; Streicher H; Ball ED; Bashey A; Soiffer RJ; Armand P
Blood; 2020 Jun; 135(24):2182-2191. PubMed ID: 32478814
[TBL] [Abstract][Full Text] [Related]
39. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
40. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]